Novel approaches to testing for sexually transmitted infections, including HIV and hepatitis B and C in Europe
This report focuses on novel approaches to testing for sexually transmitted infections, human immunodeficiency virus, hepatitis B virus and hepatitis C virus that are relevant for the prevention and control of these infections at EU/EEA level.
EMIS 2010: The European Men-Who-Have-Sex-With-Men Internet Survey
This report comprises the findings of an internet survey among men who have sex with men (MSM) from 38 European countries, making a total sample of over 180 000 men across Europe.
Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA
This report presents the main findings of an ECDC project to assess the burden of infectious diseases among migrants in the EU/EEA based on available data for specific diseases: human immunodeficiency virus (HIV), tuberculosis (TB), hepatitis B, hepatitis C, gonorrhoea, syphilis, measles and rubella, malaria and Chagas disease.
Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA: Executive summary
Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies
This literature review answers a series of questions on the prevalence of chronic HBV and HCV infection in the general EU population, the number of individuals with chronic HBV or HCV infection, and current national practices for screening for chronic HBV and HCV infection, all with the overarching goal of promoting national and European policies on the secondary prevention of these two diseases.
Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA
This report gives an overview of chronic hepatitis B and C virus infection among foreign-born migrants in the EU/EEA.
Hepatitis B and C testing activities, needs, and priorities in the EU/EEA
ECDC undertook a survey to assess needs and priorities prior to developing guidance on testing and screening for hepatitis B and C (HBV/HCV) in the EU/EEA, and to update the existing evidence on the burden of HBV/HCV morbidity and mortality across EU/EEA Member States.